- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07597291
Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) (COR-SHOCK)
Cardiovascular Outcomes Registry in Cardiogenic SHOCK
The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:
- How have management strategies and clinical outcomes for cardiogenic shock evolved over time?
- How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?
Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.
Participants will:
- Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced).
- Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay.
- Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
The Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) is hybrid (retrospective and prospective), observational registry designed to evaluate the clinical performance, therapeutic management, and outcomes of patients presenting with cardiogenic shock (CS).
Contemporary CS management has evolved beyond correcting macro-hemodynamic parameters. CS is now recognized as a highly dynamic, systemic syndrome characterized by microvascular hypoperfusion, systemic inflammatory response syndrome (SIRS), endothelial dysfunction, and profound neurohormonal and metabolic derangements. To capture this complexity, the COR-SHOCK registry systematically integrates granular, real-world data reflecting these pathophysiological axes. This includes laboratory evaluation, and advanced invasive hemodynamic profiling via pulmonary artery catheterization (Swan-Ganz).
Registry Procedures and Quality Assurance Plan
To ensure high-quality data collection and compliance with scientific standards, the registry implements the following procedures:
Quality Assurance (QA) Plan:
The Steering Committee, led by the Principal Investigator, oversees the registry's operations. Internal data quality audits are conducted semi-annually to review enrollment rates, evaluate protocol adherence, and identify systematic data entry discrepancies.
Data Checks:
Data is transcribed from electronic health records into a dedicated electronic database. The entry platform utilizes programmed range validation and consistency rules (e.g., preventing physiological out-of-range values for hemodynamics and laboratory results, and enforcing logical chronological order for clinical events, such as ensuring discharge dates succeed admission dates).
Source Data Verification (SDV):
To guarantee data accuracy and completeness, a designated researcher who is not directly involved in the primary data entry performs random source data verification on 10% of all registry entries. This process involves cross-referencing database records with original paper and electronic health records.
Data Dictionary:
A comprehensive data dictionary has been established, detailing every variable collected. It defines clinical terminology, laboratory reference ranges, and standardized categorization rules.
Standard Operating Procedures (SOPs):
Formal SOPs govern all key registry processes, including:
- Daily screening and identification of eligible patients in the cardiac intensive care unit (UNICOR).
- Standardized timing for dynamic data collection.
- Data security protocols, including patient pseudonymization and password-protected access control.
- Event reporting protocols for predefined clinical complications.
- Sample Size Assessment:
The registry aims to include approximately 750 to 800 patients. This target is calculated based on historical admission rates at the center, comprising a retrospective cohort of approximately 500 patients (2017-2025) and a prospective recruitment target of 80 to 100 patients annually over a 2-to-3-year period. This sample size provides sufficient statistical power to characterize temporal trends, evaluate subset populations (e.g., mechanical circulatory support, specific etiologies), and perform robust multivariable risk modeling.
Statistical Analysis Plan (SAP) Descriptive statistics will characterize the study population. Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), based on normality (assessed via Shapiro-Wilk test). Categorical variables will be expressed as frequencies and percentages.
To evaluate management and outcome trends over the years:
- Temporal trends in clinical management, therapeutic choices (such as the use of short-duration mechanical circulatory support [VA-ECMO, Impella, IABP] or advanced therapies [LVAD, cardiac transplantation]), and survival will be assessed using linear/logistic regression models across calendar years.
- Survival curves will be estimated using the Kaplan-Meier method and compared across different clinical phenotypes, therapeutic interventions, and time epochs using the log-rank test.
- Multivariable Cox proportional hazards regression and logistic regression models will be constructed to identify independent clinical, laboratory and hemodynamic predictors of short-term (ICU and in-hospital) and long-term (1 year) mortality. Model fit and calibration will be evaluated using standard diagnostic metrics (e.g., Harrell's C-index).
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: João Presume, MD
- Puhelinnumero: 3134 +351 21 043 1000
- Sähköposti: jppereira@ulslo.min-saude.pt
Opiskelupaikat
-
-
Lisbon District
-
Carnaxide, Lisbon District, Portugali, 2790-134
- Rekrytointi
- Unidade Local de Saúde de Lisboa Ocidental
-
Ottaa yhteyttä:
- João Presume, MD
- Puhelinnumero: +351 21 043 1000
- Sähköposti: jppereira@ulslo.min-saude.pt
-
Ottaa yhteyttä:
- Catarina Brízido, MD
- Puhelinnumero: +351 21 043 1000
- Sähköposti: cbrizido@ulslo.min-saude.pt
-
Päätutkija:
- João Presume, MD
-
Alatutkija:
- Catarina Brízido, MD
-
Alatutkija:
- Ana Rita Bello, MD
-
Alatutkija:
- Christopher Strong, MD
-
Alatutkija:
- Manuel Sousa Almeida, PhD
-
Alatutkija:
- Jorge Ferreira, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
-Cardiogenic shock according to the following criteria:
Cardiac disorder resulting in hypotension, defined as at least one of the following:
- Systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or
- Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg
AND
Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:
- Serum lactate >2 mmol/L
- Acute kidney injury and/or oliguria
- Acute hepatic injury
- Cool or mottled extremities
- Altered mental status
AND
Clinical presentation judged to be primarily attributable to a cardiac etiology.
Exclusion Criteria:
- Age < 18 years.
- Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).
- Refusal to participate in the study (applicable only to the prospective cohort).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Cardiogenic Shock Registry Cohort
Adult patients admitted with a diagnosis of cardiogenic shock between January 2017 and the end of the prospective recruitment period.
All patients receive contemporary, standard clinical management for cardiogenic shock as determined by the clinical team, with no experimental interventions.
Clinical, laboratory, imaging, and advanced hemodynamic monitoring data are systematically collected from hospital records to evaluate clinical performance and outcomes over time.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
All-Cause Mortality at 30 days after admission
Aikaikkuna: From date of hospital admission to 30 days after admission
|
The proportion of patients presenting with cardiogenic shock who die from any cause during the first 30 days after admission
|
From date of hospital admission to 30 days after admission
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
All-Cause Mortality at 1 Year
Aikaikkuna: At 1 year post-index admission.
|
The rate of all-cause mortality evaluated after the index admission.
Survival status will be determined via electronic medical records or the national registry ("last seen alive" verification).
|
At 1 year post-index admission.
|
|
Incidence of Major Bleeding up to 30 days after admission
Aikaikkuna: From date of hospital admission to 30 days after admission
|
The proportion of patients experiencing major bleeding events up to 30 days after admission.
Major bleeding is defined according to the Bleeding Academic Research Consortium (BARC) classification as Type 3 (including 3a, 3b, and 3c) or Type 5 (fatal bleeding).
|
From date of hospital admission to 30 days after admission
|
|
Incidence of 3-Point Major Adverse Cardiovascular Events (3P-MACE) at 30 days
Aikaikkuna: From date of hospital admission to 30 days after admission
|
Thrombotic/ischemic events are defined using the 3-point Major Adverse Cardiovascular Events (3P-MACE) composite, which includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke at 30 days after admission.
|
From date of hospital admission to 30 days after admission
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Rate of Long-term Ventricular Assist Device (LVAD) Implantation or Heart Transplantation
Aikaikkuna: Up to 1 year post-index admission.
|
The percentage of patients transitioning to advanced, long-term therapeutic options, specifically durable Left Ventricular Assist Devices (LVAD, e.g., HeartMate 3) or undergoing heart transplantation as a bridge or destination therapy.
|
Up to 1 year post-index admission.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation. 2017 Oct 17;136(16):e232-e268. doi: 10.1161/CIR.0000000000000525. Epub 2017 Sep 18.
- Kolte D, Khera S, Aronow WS, Mujib M, Palaniswamy C, Sule S, Jain D, Gotsis W, Ahmed A, Frishman WH, Fonarow GC. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. J Am Heart Assoc. 2014 Jan 13;3(1):e000590. doi: 10.1161/JAHA.113.000590.
- Thiele H, Ohman EM, de Waha-Thiele S, Zeymer U, Desch S. Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J. 2019 Aug 21;40(32):2671-2683. doi: 10.1093/eurheartj/ehz363.
- Kapur NK, et al. Mechanical circulatory support in cardiogenic shock. J Am Coll Cardiol. 2020.
- Garan AR, et al. Complete hemodynamic profiling in cardiogenic shock. J Am Coll Cardiol. 2020.
- Monnet X, Messina A, Greco M, Bakker J, Aissaoui N, Cecconi M, Coppalini G, De Backer D, Edul VK, Evans L, Hernandez G, Hunsicker O, Ince C, Kaufmann T, Levy B, Malbrain MLNG, Mebazaa A, Myatra SN, Ostermann M, Pinsky MR, Saugel B, Savi M, Singer M, Teboul JL, Vieillard-Baron A, Vincent JL, Chew MS. ESICM guidelines on circulatory shock and hemodynamic monitoring 2025. Intensive Care Med. 2025 Nov;51(11):1971-2012. doi: 10.1007/s00134-025-08137-z. Epub 2025 Nov 14.
- Krychtiuk KA, Vrints C, Wojta J, Huber K, Speidl WS. Basic mechanisms in cardiogenic shock: part 1-definition and pathophysiology. Eur Heart J Acute Cardiovasc Care. 2022 Jun 7;11(4):356-365. doi: 10.1093/ehjacc/zuac021.
- Hochman JS, et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome. N Engl J Med. 1999.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- HSantaCruz
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual Participant Data (IPD) will not be publicly shared to protect patient confidentiality and ensure strict compliance with legal and ethical standards. This study is conducted in accordance with the European Union General Data Protection Regulation (GDPR) and Portuguese Data Protection Law (Lei n.º 58/2019).
De-identified, aggregated data or specific proposals for collaborative academic research may be considered upon reasonable request, subject to approval by the study's Steering Committee and the institutional Ethics Committee (contact via jppereira@ulslo.min-saude.pt).
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Kardiogeeninen shokki
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRekrytointiShock Wave -hoito polvilumpion tulehdukselleKiina
-
Hospital General de México Dr. Eduardo LiceagaRekrytointiFotopletysmografia | Shock Septic | AaltomuotoMeksiko
-
University Hospital, BordeauxValmisKardiogeeninen shokki | Lyhytaikainen mekaaninen verenkiertotuki | Shock TeamRanska
-
La Jolla Pharmaceutical CompanyValmisSepsis | Katekolamiiniresistentti hypotensio (CRH) | Distributiivinen shokki | High Output ShockYhdysvallat
-
La Jolla Pharmaceutical CompanyValmisSepsis | Katekolamiiniresistentti hypotensio (CRH) | Distributiivinen shokki | High Output ShockYhdysvallat, Kanada, Belgia, Australia, Yhdistynyt kuningaskunta, Suomi, Uusi Seelanti, Ranska, Sveitsi, Saksa
-
La Jolla Pharmaceutical CompanyRekrytointiSeptinen shokki | Katekolamiiniresistentti hypotensio (CRH) | Distributiivinen shokki | High Output ShockBelgia, Liettua
-
La Jolla Pharmaceutical CompanyHyväksytty markkinointiinSepsis | Vasodilatatorinen shokki | Distributiivinen shokki | High Output Shock | Katekolamiiniresistentti hypotensio (CRH)
-
University of OxfordValmisHengitysvajaus | Hengityksen vajaatoiminta | Hengitysvaikeusoireyhtymä | Shock LungYhdistynyt kuningaskunta
-
Cairo UniversityEi vielä rekrytointiaPiriformis-lihasoireyhtymä | Kehonulkoinen shokkiaalto | Radial Shock Wave | Matalan tason laserEgypti
-
Medical University of ViennaTuntematonAkuutti maksan vajaatoiminta | Hypoksinen hepatiitti | Iskeeminen hepatiitti | Shock Maksa | Hypoksinen maksavaurioSaksa, Itävalta